about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesMonoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.TP53 mutation and survival in chronic lymphocytic leukemia.Targeting the BRAF V600E mutation in multiple myeloma.Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisSubcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.Chronic lymphocytic leukemia and 13q14: miRs and more.Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemiaEvolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemiaExploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskDetection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.BRAF inhibitor therapy in HCL.BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survivalDNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaRisk categories and refractory CLL in the era of chemoimmunotherapy.Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications.Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.From pathogenesis to treatment of chronic lymphocytic leukaemia.Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).Understanding and managing ultra high-risk chronic lymphocytic leukemia.Importance of genetics in chronic lymphocytic leukemia.Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay.Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia.BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells.Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
P50
Q26748775-A83E82AC-3ECB-4061-9F49-9ABABEEC4E85Q27851444-6DE3DC3A-AB12-4724-8D06-78CC5CB88666Q27851577-560B148B-9F75-44FF-94B5-7B4D17FF2F60Q27852220-57C8D7D4-06C4-4B9A-AB0D-5CECF6432A0DQ30235460-5548624F-D0A0-4274-BF45-717B81DF42D1Q30840070-E3CA6920-A148-4F93-9E7E-2AB9BDD311B2Q33385371-3FF0087E-A943-42D8-96BF-E70D0D462070Q33426999-6CC567F6-F2AF-46CA-A6FD-6A59CD68D096Q33587644-813BBCCB-4B8D-44C9-867A-8C4937D751BAQ34052080-6BDB9C77-E2BB-4667-922D-6D3E182D1828Q34056568-E0EF65A3-C20B-4A8A-BFA7-3EF670064842Q34255118-5892B378-D847-4E6D-A973-4BEC29AE03A4Q34371069-BCE3E067-5D2F-4057-9514-2D09038ACCD2Q34473466-C76B36F6-43F9-4535-BA05-8CC3140EFADFQ34503374-495924C2-7B35-4AD7-B2B9-459ECEBCCCB2Q35140116-40AEC154-6413-4685-9583-A751AE30B04FQ35483665-6FAE8524-E582-4BAE-A9B4-428A268AA30EQ35506520-C1CE16A5-2F87-4EEB-97CA-3C776385A982Q36914078-2F000C4E-3E1B-4D5E-90AD-B1277EB08C38Q36925503-BE7E930F-6A5E-4E47-97E1-313A6F4E0ECAQ36931139-C3CC8A61-1588-45A4-B824-668A6887BE98Q37130889-ED14081B-383B-4538-A88D-BEAC7A3017ACQ37141887-67EA04C8-D7D7-4B0C-A2B5-E2460474B114Q37152757-7DB9F969-D0F3-464D-A0DB-5066CD029874Q37355522-333877B1-BE18-4EEB-9A3D-8E4D5D04C961Q37434174-E1DE64D5-7385-4259-BE14-DC11D3C6B479Q37623386-50EB5BA3-A6CE-458D-BC40-EE03F41F23CFQ37643423-D2FD9920-4AB2-4BF0-AA12-3E16DEA0F1FEQ37771666-9ACE5A0C-15A1-43D6-BD39-509E27768BF4Q37829257-2AFE9C36-E6CD-4B44-9CBB-2131EBF07914Q37857481-F6C0FBB5-56E5-45FA-B47F-A717F67FDD4BQ37975154-AA840D1C-3FE4-4894-B4C7-CD143FF61C3EQ38101382-BB34321F-EB17-4F10-BA63-07330C1B4FF7Q38348762-C68CA65C-033E-4CAF-900C-AEC660649EC4Q38628202-338FB13D-F37D-4CCD-978B-C95AAF80A4EEQ38722432-9258B5B4-FE47-41CE-8639-297BEF6BA0DCQ38907126-EDC56311-57BC-4B9C-878E-6AECF9276FDEQ38973214-233D86F9-20D1-481E-B186-C130C2CA3955Q39113026-EE9B724E-7647-490B-9AD1-7923CABA6723Q39349837-2EB7DF3E-45E5-49B0-9A49-F97BE510B9C7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Thorsten Zenz
@ast
Thorsten Zenz
@en
Thorsten Zenz
@es
Thorsten Zenz
@nl
Thorsten Zenz
@sl
type
label
Thorsten Zenz
@ast
Thorsten Zenz
@en
Thorsten Zenz
@es
Thorsten Zenz
@nl
Thorsten Zenz
@sl
prefLabel
Thorsten Zenz
@ast
Thorsten Zenz
@en
Thorsten Zenz
@es
Thorsten Zenz
@nl
Thorsten Zenz
@sl
P214
P106
P21
P214
P31
P496
0000-0001-7890-9845
P7859
viaf-13023841